23 May 2016
LivaNova PLC (the “Company” or “LivaNova”) announces on 23 May 2016, that Hugh M. Morrison, who is a PDMR and Director of LivaNova, on 19 May 2016 disposed of 3,600 ordinary shares of £1.00 each in the capital of the Company (the “Ordinary Shares”) for a price of US $48.00 per Ordinary Share. As a result of this transaction, Hugh M. Morrison currently holds 5,215 Ordinary Shares, representing 0.011 per cent of the Company’s issued share capital (which excludes the 1,209 Ordinary Shares that he is entitled to in relation to his Restricted Stock Units (subject to vesting periods and the terms of the LivaNova 2015 Incentive Award Plan)).
This announcement is made pursuant to the Disclosure and Transparency Rule 3.1.4R.
Further details and a copy of the applicable Form 4, “Statement of Changes in Beneficial Ownership of Securities,” to be filed with the U.S. Securities & Exchange Commission, can be found at the SEC website, www.sec.gov, and the LivaNova PLC web site, www.livanova.com.
LivaNova PLC is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide and is headquartered in London, U.K. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Surgery, Cardiac Rhythm Management, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.
For more information, please visit www.livanova.com, or contact:
Investor Relations and Media
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332